Systematic Financial Management LP Sells 49,313 Shares of Integra LifeSciences Holdings Corporation $IART

Systematic Financial Management LP trimmed its holdings in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 4.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 1,059,286 shares of the life sciences company’s stock after selling 49,313 shares during the period. Systematic Financial Management LP owned approximately 1.36% of Integra LifeSciences worth $9,978,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Global Retirement Partners LLC purchased a new stake in shares of Integra LifeSciences in the 4th quarter worth approximately $25,000. Osaic Holdings Inc. raised its stake in Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after buying an additional 1,104 shares during the last quarter. GAMMA Investing LLC raised its stake in Integra LifeSciences by 145.9% during the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after buying an additional 3,742 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Integra LifeSciences by 595.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after acquiring an additional 6,814 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Integra LifeSciences in the fourth quarter worth $124,000. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Stock Up 6.6%

Integra LifeSciences stock opened at $19.79 on Friday. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -3.06, a PEG ratio of 1.29 and a beta of 1.22. The stock has a fifty day simple moving average of $17.39 and a two-hundred day simple moving average of $13.31. Integra LifeSciences Holdings Corporation has a 12 month low of $8.70 and a 12 month high of $20.26. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.13. The firm had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company’s revenue was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on IART. Citigroup reissued a “neutral” rating and issued a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Thursday, June 18th. BMO Capital Markets initiated coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price target on the stock. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. Finally, Wells Fargo & Company raised their price objective on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $18.33.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.